Advancing Non-Invasive Cancer Prediction in Lynch Syndrome
PREDI-LYNCH (Validated non-invasive liquid biopsy tests for cancer PREDIction in LYNCH Syndrome) is a groundbreaking pan-European project funded by the European Union HORIZON-MISS-2024-CANCER-01-03 mission on cancer (Grant Number 101213916).
This ambitious initiative aims to transform early cancer detection of individuals with Lynch syndrome (LS) - a hereditary condition that significantly increases the risk of colorectal, gynecological, and urothelial cancers – implementing non-invasive, accurate and cost-effective solutions.
The Challenge
Lynch Syndrome affects approximately 1 in 440 people of European ancestry, yet only 5% of the 2 million estimated LS carriers in Europe under cancer surveillance. This gap highlights an urgent need to improve early detection of cancer in LS.
Our Vision
PREDI-LYNCH aims to develop and validate non-invasive, accurate, and cost-effective liquid biopsy tests to detect cancer at its earliest stages in LS carriers. By moving beyond traditional, often invasive diagnostic methods, the project seeks to deliver a more acceptable and scalable solution for long-term cancer surveillance.
Our Role
As a key technology partner, Elypta will apply its proprietary GAGome-based biomarker platform—which analyzes glycosaminoglycan profiles in plasma and urine—to detect early biochemical changes associated with cancer. This approach offers a unique and highly sensitive method for early cancer detection.
The project
Launching on May 1, 2025 and coordinated by Oslo University Hospital, PREDI-LYNCH brings together 27 leading partners across Europe, including research hospitals, biotech companies, and patient advocacy groups. The project will collect plasma and urine samples from approx. 2000 LS carriers making it one of the largest real-world studies of its kind.
Impact
By delivering a validated, real-world-tested screening tool, PREDI-LYNCH aims to:
